Pharmacy

Pharmaceutical Companies

Improved chronic medication adherence equals improved sales.

Patient Retention Strategy

Adherence Management

Data of the World Health Organisation (WHO) provides that 50% of chronic sales disappear at patient level due to poor adherence. Without the implementation of proper adherence programmes, this drop can severely affect annual sales volumes and have further financial implications.

By implementing the right adherence programme, you can prevent these drop offs, and your sales force and marketing strategies will begin to fuel the growth of your product line.

Drug Utilization Programs

The drug utilization and adherence management programme is twofold.

First, alternative medication is offered to the patient in terms of section 22F of the Medicines and Related Substances Act 101 of 1965. Once the patient accepts the alternative medication, he/she will receive a monthly call to ensure the patient’s continuation with therapy and compliance with the prescribed treatment regimen.

Patient & Reimbursement Support

The Health Window Patient Support Programme (PSP) incorporates key patient touchpoints to ensure access to treatment, treatment adherence, and the continuation of treatment adherence.

Patient
Enrollment

Receive application & create a web-based profile to enable one view of the patient’s treatment journey.

Introduction
Call

First key contact with patient – introduction to PSP & capture metrics relevant to the customized programme.

Reimbursement

Submission of completed application to the funders & follow up on outcome.

Disease
& Product

Key Care Path Triggers based on patient segmentation.

Compliance
Monitoring

Arrange delivery and trigger script and autorization expiry reminders.

12 Reasons why Health Window should be your First Choice

  • 17 Years’ Experience
  • In-Depth Industry Knowledge
  • Established Industry Relationships
  • Multi-Channel Accelerated Patient Enrolment (Healthcare Practitioners and Health Window Pharmacy Partners)
  • Verified Pre-Approved Patient Consent Through Our Partner Networks
  • Proven Success in Reimbursement Outcomes
  • Interactive Real-Time Live Reporting Dashboards
  • Flexible And Agile Adaption to Client Needs
  • Wide Variety of Customized Digital Solution Platforms Developed to Suit Our Client’s Needs
  • Access To Patient Specific Adherence Data Through Our Pharmacy Partner Network
  • Comprehensive View of Patient Medication Utilization
  • Multichannel Engagement with Patients and Partners
  • Well Established Quality Control Procedures and Pharmacovigilance Compliance

Data Analytics

Two key factors that play an important role in sales growth are: gaining a new patient; and retaining the new patient.

Other parties provide sales data that fails to address the need to track a patient’s treatment journey.

At Health Window we utilize patient level data supported by comprehensive data analytics to identify and understand the factors that influence the full patient treatment journey.

We are committed to easing the user experience. The complicated data relationships are illustrated in easy-to-understand interactive reporting that encompasses all the critical data points.

Factors influencing the new script

At Health Window, we merge multiple data sets (age, gender, healthcare providers, location, treatment duration, comorbidities, medical aid, healthcare administrator, front-shop sales, and cash payment) into machine learning models to pinpoint the primary factors that affect the new script.

Factors influencing patient retention

According to WHO, medication adherence in developed countries is typically at 50%.

Through the implementation of machine learning across multiple data sets, we are able to identify and report on the factors that influence patient retention and its impact on sales. 

The reasons for non-adherence may include generic substitution, therapeutic switching, failure to obtain a new script, switching pharmacies, and reimbursement.

Realworld outcomes

In the real world, non-adherence to therapy detracts from optimal outcomes and this is why we cannot rely on clinical trial result in a ‘real-world’ setting.

The gap between clinical trial results and real-world efficacy can be bridged through the implementation of programmes that improve patient adherence.

A doctor is more likely to switch a patient’s medication due to sub-optimal results (although caused by the patient’s non-adherence). Therefore, if a patient is adherent doctors are less likely to switch patients to other drugs.